Synthetic Biologics Stock Price - SYN

0.00 (0.0%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Synthetic Biologics Inc SYN AMEX Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.41 0.00 0.00 0.00 0.41 04:42:03
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.41 USD

Synthetic Biologics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.49M 18.26M 12.70M $ - $ - -0.98 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
6.20k $ - 0.00% - -

more financials information »

Synthetic Biologics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SYN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.380.430.34880.3961114345,4520.037.89%
1 Month0.33250.52270.25250.3557178403,4510.077523.31%
3 Months0.35940.52270.250.3426413300,2470.050614.08%
6 Months0.4110.790.250.4147564290,820-0.001-0.24%
1 Year0.53410.790.250.4284715189,119-0.1241-23.24%
3 Years24.67536.750.2513.29598,359-24.27-98.34%
5 Years84.00151.200.2542.06777,624-83.59-99.51%

Synthetic Biologics Description

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.